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Dockinga b s t r a c t
Cladosporols are secondary metabolites from Cladosporium tenuissimum characterized for their ability to
control cell proliferation. We previously showed that cladosporol A inhibits proliferation of human colon
cancer cells through a PPARc-mediated modulation of gene expression. In this work, we investigated cla-
dosporol B, an oxidate form of cladosporol A, and demonstrate that it is more efficient in inhibiting HT-29
cell proliferation due to a robust G0/G1-phase arrest and p21waf1/cip1 overexpression. Cladosporol B acts
as a PPARc partial agonist with lower affinity and reduced transactivation potential in transient transfec-
tions as compared to the full agonists cladosporol A and rosiglitazone. Site-specific PPARc mutants and
surface plasmon resonance (SPR) experiments confirm these conclusions. Cladosporol B in addition dis-
plays a sustained proapoptotic activity also validated by p21waf1/cip1 expression analysis in the presence
of the selective PPARc inhibitor GW9662. In the DMSO/H2O system, cladosporols A and B are unstable
and convert to the ring-opened compounds 2A and 2B. Finally, docking experiments provide the struc-
tural basis for full and partial PPARc agonism of 2A and 2B, respectively. In summary, we report here,
for the first time, the structural characteristics of the binding of cladosporols, two natural molecules,
to PPARc. The binding of compound 2B is endowed with a lower transactivation potential, higher antipro-
liferative and proapoptotic activity than the two full agonists as compound 2A and rosiglitazone (RGZ).
 2016 Elsevier Inc. All rights reserved.1. Introduction
Natural molecules isolated and characterized from plants, fungi
and microorganisms represent a source of new drugs for cancertreatment. Their employment is advantageous because they gener-
ally are less expensive and act as multitargeted therapeutics, a fea-
ture that is absolutely beneficial to the treatment of solid tumors
caused by dysregulation of several genes. Natural compounds usu-
ally have lower affinity and thus lower toxicity than synthetic
drugs so that they do not interfere with most of the essential
biological functions.
Among natural compounds, carotenoids, flavonoids, organosul-
furs, isothiocyanates, indoles and monoterpenes have been associ-
ated with a reduced risk of cancer in a large series of
epidemiological and preclinical studies [1–3]. In addition, they
are very useful in the management of cancer patients either alone
or in combination with known molecules [4–6].
In the search for novel natural molecules, we recently demon-
strated that cladosporol A, a secondary metabolite from Cladospo-
rium tenuissimum, exhibits antiproliferative properties in a variety
Fig. 1. Chemical structures of cladosporol A and B.
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cycle gatekeeper gene expression (p21waf1/cip1, cyclin D1, cyclin E,
CDK2, CDK4) [7]. These effects aremediated by PPARc to which Cla-
dosporol A binds as a ligand, activating, in turn, p21waf1/cip1 gene
expression in an Sp1-dependent manner [8]. Cladosporol A-bound
PPARc targets b-catenin to proteasomal degradation, reducing the
overall amount of the protein and transcription of its target genes
[8]. In addition, it stimulates E-cadherin gene transcription, further
supporting the anti-metastatic activity of this compound [8]. These
results are consistent with the data from literature disclosing for
PPARc a protective role in in vitro and in vivo colorectal cancer
(CRC) models [9–13]. In the gastrointestinal tract, in fact, PPARc
impairs cellular proliferation, stimulates differentiation and
induces apoptosis [14]. Both in sporadic CRCs and rodent models
PPARc hampers tumor initiation/progression acting as a tumor sup-
pressor [15]. CRC derived cells and transplanted tumors in nude
mice undergo growth inhibition, G0/G1 arrest and caspase-
activated apoptosis and differentiation upon treatment with
selective ligands, such as thiazolinediones (TZDs) or 15-deoxy-
D12,14-prostaglandin J2 [16,17]. Moreover, ligand-bound PPARc
regulates lipid and carbohydrate metabolism, adipogenesis, insulin
sensitization, inflammation, atherosclerosis [18–20]. It is conceiv-
able that such a wide range of functions implies different binding
modalities of the selective ligands to the receptor ligand binding
domain (LBD) and interactions with protein partners activating dif-
ferent pathways involved in the control of metabolism, prolifera-
tion or differentiation. Such a choice likely depends on the
amount of the receptor available in a given cell, the chemical fea-
tures of the ligands and their affinity for the receptor. The ligands,
moreover, induce conformational changes to the PPARc LBD that
influence the recruitment of functional effectors (coactivators,
corepressors, molecular adapters, chromatin modifying enzyme
activities etc.) that in turn stimulate the formation of an open chro-
matin and activation of a wide range of gene transcription. Many of
these genes are involved in glucose and lipidmetabolism, thus TZD-
activated PPARc ameliorates diabetic patients’ conditions [21–24].
Unfortunately, these synthetic TZDs cause undesired side- and off-
target effects (higher rate of bone fractures, weight gain, edema,
renal function failure, etc.) [25–27]. More recently, identification
and characterization of specific PPARc ligands known as SPPARMs
(Selective PPARc Modulators), displaying beneficial antidiabetic
action with no or reduced side-effects, are gaining interest [28–30].
In line with this reasoning, to obtain novel molecules that could
act as PPARc agonists and inhibit CRC development, we selected
cladosporol B, an oxidate form of cladosporol A, and investigated
its antiproliferative and proapoptotic properties in comparison
with cladosporol A (Fig. 1). Here, we demonstrate that cladosporol
B displays anticancer activity in HT-29 cells due to not only a G0/G1
cell cycle arrest via p21waf1/cip1 early overexpression, but also a
strong activation of apoptosis as evidenced by experiments in
different cell lines in the presence of GW9662, a specific PPARc
inhibitor. The effects of cladosporol B are more pronounced than
those of cladosporol A and correlate with a lower affinity for the
PPARc LBD and a reduced PPRE-mediated transactivation potential.
Surface plasmon resonance (SPR) experiments and site-specific
PPARc mutants confirmed these conclusions. Proton nuclear mag-
netic resonance (1H NMR) and high resolution electrospray ioniza-
tion mass (HR-ESI-MS) were used to elucidate the epoxide ring
opening reaction of cladosporols A and B in dimethyl sulfoxide
(DMSO)/H2O system to form the corresponding PPARc active com-
pounds 2A and 2B. Moreover, we report and compare the 3D struc-
tures of the PPARc LBD in the complex with 2A and 2B, providing a
molecular explanation for their different behavior as full and partial
PPARc agonists, respectively. The stronger antiproliferative activity
of cladosporol B might correlate with a differential binding to the
PPARc LBD as compared to cladosporol A.2. Materials and methods
2.1. Cells, antibodies and reagents
HT-29, RKO and HEK293 cells were obtained from the American
Type Culture Collection (Rockville, MD, USA). HT-29 cells bear dif-
ferent genetic abnormalities typical of human CRC, such as a
mutated Tp53 (Arg 273 His) and a wild-type RAS allele [31].
Antibodies against p21waf1/cip1, b-actin and caspase 3 precursor
were purchased from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Anti-mouse and anti-rabbit IgG peroxidase-linked secondary
antibodies, ECL and ECL Plus Western blotting detection kit were
purchased from Amersham Life Science (Little Chalfont,
Buckinghamshire, UK). D-MEM (Dulbecco’s Modified Eagle’s
Medium), D-luciferin sodium salt, trichloroacetic acid, propidium
iodide (PI), rosiglitazone (RGZ) and GW9662 were from Sigma
Aldrich (St. Louis, MO, USA). Fetal bovine serum (FBS), penicillin–
streptomycin, L-glutamine, trypsin–EDTA and OptiMEM I were
obtained from Gibco (Carlsbad, CA, USA). Charcoal/dextran-treated
FBS was purchased from Hyclone (Logan, Utah, USA). Fetal calf serum
(FCS), Lipofectamine 2000, CellTiter Aqueous One Cell Proliferation
Assay were obtained from Promega (Madison, WI, USA).
2.2. Cell culture and cladosporol A and B treatments
Human colon adenocarcinoma HT-29 or RKO cells were grown
as a monolayer in D-MEM containing 10% FBS, 1% penicillin–strep-
tomycin and 1% L-glutamine. The cells were cultured in 100 mm
plates, at 70–80% confluence, in a 5% CO2 humidified atmosphere,
at 37 C. Cladosporol A and B (Fig. 1) treatments were carried out
in the presence of 10% charcoal/dextran-treated FBS containing
1% penicillin–streptomycin and 1% L-glutamine, whereas the cells
were maintained at 50% confluence. Cladosporol A and B were dis-
solved in DMSO and mixed with fresh medium to achieve the final
concentration. In all treatments, the DMSO final concentration in
the mediumwas less than 0.1%. In separate experiments, cells were
treated with increasing concentrations of cladosporol A and B, for
the indicated times.
2.3. Cell viability
The growth rate of HT-29 cells was evaluated using the CellTiter
Aqueous One Cell Proliferation Assay (Promega, Madison, WI, USA),
as previously described [7]. To further evaluate cell growth after
treatment with cladosporol A and B, cells were plated in 12-well
plates at a density of 106 cells/cm2. After treatment, the cells were
washed with PBS, trypsinized and collected in culture medium. Cell
counting was performed as previously reported [7].
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HT-29 cells were plated at similar confluency, as described
above, and after 24 h, synchronized by a 48 h serum deprivation
in 0.1% FBS. An aliquot of the cells was stimulated with 2.5 and
5 lM of cladosporol B for different times (4, 8, 12, 24 and 48 h)
in the presence of D-MEM containing 10% FBS. Another aliquot of
cells was allowed to grow again in the complete medium for the
same times; these samples were used as control. After treatment,
the evaluation of DNA cell content was performed by FACS analysis
as previously described [7].
2.5. Western blotting analysis
Treated and untreated cells were lysed in Ripa buffer (150 mM
NaCl, 50 mM Tris–HCl, pH 7.6, 10 mM EDTA, 1% NP-40) containing
also a protease inhibitors cocktail and then centrifugated at 17,000
RCF for 10 min, at 4 C. Supernatant containing total proteins was
quantified and 80 lg of each sample were separated on 12%
SDS–PAGE. Western blotting assays were carried out as previously
reported [7].
2.6. DNA fragmentation assay
DNA fragmentation assay was carried out treating HT-29 cells
with 20 lM cladosporol A and, simultaneously, with 5 lM cla-
dosporol B for different times (12, 24, 48 and 72 h). After treat-
ment, the cells were harvested and washed with 1 ml of PBS,
resuspended in 100 ll of PBS. The cells were spun down at
1000g, lysed in lysis buffer (Tris–HCl 50 mM, EDTA 10 mM, N-
lauroylsarcosine 0,5%, proteinase K 0.1 mg/ml) and incubated for
6 h at 55 C. During the incubation RNAase 1 lg/ml was added
(Sigma Aldrich, St. Louis, MO, USA). After incubation for 30 min
at 37 C, 3 ll of a proteinase K (Sigma Aldrich, St. Louis, MO,
USA) solution was added and incubated for additional 30 min at
37 C. Gel loading buffer (0.25% bromophenol blue, 0.25% xylene
cyanol, 30% glycerol) was added and the entire content of the tube
transferred to 1.5% agarose gel and electrophoresed at 2 V/cm for
16 h. The DNA present was visualized under UV light after staining
with ethidium bromide.
2.7. Plasmids and transient transfection experiments
PPARc1 overexpression was obtained using a PCDNA3 vector
carrying a FLAG-tagged complete PPARc1 cDNA. PPRE-Luc plasmid
has a luciferase reporter gene under the transcriptional control of
the herpes simplex thymidine kinase (TK) promoter fused to three
copies of the PPRE derived from Acyl-CoA oxidase gene. As an
internal control for all transient transfection assays, we used the
RSV-bGal plasmid, expressing b-galactosidase gene driven by the
strong Rous Sarcoma Virus (RSV) promoter. The day before tran-
sient transfection, HEK293 and RKO cells stably expressing FLAG-
PPARc1 were plated in 12-well plates to reach 70% confluence.
After 24 h, growth medium was replaced with OPTI-MEMI, with-
out serum and antibiotics, and cells were transfected with the luci-
ferase reporter gene (PPRE-Luc) using lipofectamine 2000 reagent
according to the manufacturer’s instructions. About 10–12 h after
transfection, cells were washed and treated with different concen-
trations of RGZ, cladosporol A and B. The same protocol was used in
the cotransfection experiments with FLAG-PPARc1 wt and its
mutated form (C285A). Similar conditions in transfection assays
were also used when the cells were treated with GW9662 for the
indicated times and dosage. Transfection samples were carried
out in triplicate and the transactivation activities evaluated by luci-
ferase assay. The values were normalized by b-galactosidase assay
and the average value for each triplicate was calculated.2.8. SPR measurements
SPR analyses were carried out using a Biacore 3000 optical
biosensor (Little Chalfont, Buckinghamshire, UK) according to our
previously published procedures [32]. Briefly, a PPARc LBD surface
and a BSA surface were prepared on a research-grade CM5 sensor
chips (Little Chalfont, Buckinghamshire, UK). Proteins (50 lg/ml in
10 mM CH3COONa, pH 5.3) were immobilized using standard
amine-coupling protocols to obtain densities of 5–8 kRU. Cla-
dosporol A and B were dissolved in 100% DMSO to obtain 4 mM
solutions, and then diluted in Phosphate-Buffered Saline (PBS).
For each molecule a six-point concentration series spanning
0.025–1 lM was set up. Final DMSO concentration was set to
0.1%. SPR experiments were carried out using a 50 ll/min flow rate,
at 25 C. Association and dissociation times were set at 60 s and
300 s, respectively. To yield kinetics and thermodynamic parame-
ters of complex formation sensorgrams were fit to a single-site
bimolecular interaction model using BIAevaluation software (Little
Chalfont, Buckinghamshire, UK).2.9. 1H NMR and HR-ESI-MS analysis of cladosporols A and B
All deuterated solvents (DMSO-d6, 99.9 atom%; D2O, 99.9 atom
%) were purchased from Sigma–Aldrich. 1H NMR spectra were
recorded at 25 C using a Bruker Avance 600 MHz instrument.
DMSO-d6/D2O mixture was used as solvent and TMS as an internal
standard. All numbers referring to NMR data obtained are in parts
per million (ppm). HR-ESI-MS spectra were obtained by means of a
Thermo LTQ Orbitrap XL mass spectrometer. The spectra were
recorded by infusion into the ESI source using MeOH dry as the
solvent.2.9.1. (1aR,7R,7aR)-6,7-Dihydroxy-3-(5-hydroxy-4-oxo-1,2,3,4-tetra-
hydronaphthalen-1-yl)-7,7a-dihydronaphtho[2,3-b]oxiren-2(1aH)-
one (cladosporol A)
1H NMR (500 MHz, DMSO-d6): d 7.36 (t, 1H; J = 8.4 Hz), 6.98 (d,
1H; J = 8.6 Hz), 6.90 (d, 1H; J = 8.6 Hz), 6.77 (d, 1H; J = 8.4 Hz), 6.15
(d, 1H; J = 8.4 Hz), 5.49 (s, 1H), 4.79 (m, 1H), 4.02 (dd, 1H; J = 4.5,
2.1 Hz), 3.83 (d, 1H; J = 4.5 Hz), 2.75 (m, 2H), 2.27 (m, 2H), ppm.
Mass: m/z = 353 (M+H, ESI+), 100%.2.9.2. (50R,60R,70S)-40,5,50,60,70-Pentahydroxy-2,3,60,70-tetrahydro-[1,
10- binaphthalene]-4,80(1H,50H)-dione (2A)
1H NMR (500 MHz, DMSO-d6): d 7.38 (t, 1H; J = 8.4 Hz), 7.08 (d,
1H; J = 8.8 Hz), 6.83 (d, 1H; J = 8.4 Hz), 6.68 (d, 1H; J = 8.6 Hz), 6.31
(d, 1H; J = 8.4 Hz), 5.15 (m, 2H), 4.72 (d, 1H; J = 9.8 Hz), 3.82 (m,
1H; J = 9.8, 3.1 Hz), 2.72 (m, 2H), 2.21 (m, 2H), ppm. Mass:
m/z = 369 (M+H, ESI+), 100%.2.9.3. (1aS,7aR)-3-Hydroxy-6-(5-hydroxy-4-oxo-1,2,3,4-tetrahydron-
aphthalen-1-yl)naphtho[2,3-b]oxirene-2,7(1aH,7aH)-dione
(cladosporol B)
1H NMR (500 MHz, DMSO-d6): d 7.68 (t, 1H; J = 8.4 Hz), 7.45 (d,
1H; J = 8.6 Hz), 7.43 (d, 1H; J = 8.6 Hz), 6.95 (d, 1H; J = 8.4 Hz), 6.33
(d, 1H; J = 8.4 Hz), 5.10 (m, 1H), 4.36 (m, 2H), 2.90 (m, 2H), 2.43 (m,
2H), ppm. Mass: m/z = 351 (M+H, ESI+), 100%.2.9.4. 40,5,50,60,70,80-Hexahydroxy-2,3-dihydro-[1,10-binaphthalen]-4
(1H)-one (2B)
1H NMR (500 MHz, DMSO-d6): d 8.70 (brs), 7.34 (t, 1H;
J = 8.6 Hz), 6.92 (d, 1H; J = 8.6 Hz), 6.82 (d, 1H; J = 8.6 Hz), 6.78 (d,
1H; J = 8.4 Hz), 6.16 (d, 1H; J = 8.4 Hz), 3.95 (m, 1H), 2.75 (m, 2H),
2.41 (m, 2H), ppm. Mass: m/z = 369 (M+H, ESI+), 100%.
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Molecular modeling and graphics manipulations were per-
formed using Maestro 10.2 (Schrödinger, LLC, New York, NY,
2015, USA) and UCSF-Chimera 1.8.1 software packages (http://
www.cgl.ucsf.edu/chimera) running on a E4 Computer Engineering
E1080 workstation provided with a Intel Core i7-930 Quad-Core
processor [33]. GOLD 5.2 (CCDC Software Limited: Cambridge,
U.K., 2008) was used for all docking calculations [34]. Figures
were generated using Pymol 1.0 (Schrödinger, LLC, New York, NY,
2015, USA).
2.11. Protein and ligand preparation
The crystal structure of PPARc complexed with the ligand LT175
(PDB code: 3B3K) [35] was recovered from the Brookhaven Protein
Data Bank (PDB), and employed for the automated docking studies.
The protein was processed through the Protein Preparation Wizard
in Maestro. All crystallographic water molecules and other chemi-
cal components were deleted, the right bond orders as well as
charges and atom types were assigned and the hydrogen atoms
were added to both proteins. Arginine and lysine side chains were
considered as cationic at the guanidine and ammonium groups,
and the aspartic and glutamic residues were considered as anionic
at the carboxylate groups. The imidazole ring of H449 and H323
into PPARc were set in their Ne2-H (N tau-H) tautomeric state.
Moreover, an exhaustive sampling of the orientations of groups,
whose H-bonding network needs to be optimized, was performed.
Finally, the protein structure was refined with a restrained mini-
mization with the OPLS2005 force field by imposing a 0.3 Å rmsd
limit as the constraint.
Molecular structures of compounds 2A and 3B were built using
the fragment dictionary of Maestro and preprocessed with LigPrep
3.4 (Schrödinger, LLC, New York, NY, 2015, USA) which prepares
the ligands in multiple protonation and tautomerization states atA B 
Fig. 2. Cladosporol B inhibits the growth of human HT-29 cell line more significantly th
cells, as determined by the CellTiter Aqueous One Cell Proliferation Assay. Cells were seed
After 24 h, cells were exposed to increasing concentrations of cladosporols (from 0.4 to 75
at 490 nm. Results were expressed as the optical density ratio of the difference between
was repeated two times. *P < 0.05, **P < 0.01, ***P < 0.005 compared with control. (B) To a
were treated or not with 2.5, 5, 10 and 20 lM of both drugs for 8, 24, 48 and 72 h, collect
duplicate. Results were similar in two independent experiments. *P < 0.05, **P < 0.01, ***Pa neutral pH. Compounds were then optimized by Macromodel
10.8 (Schrödinger, LLC, New York, NY, 2015, USA) using the MMFF
force field with the steepest descent (1000 steps) followed by trun-
cated Newton conjugate gradient (500 steps) methods. Partial
atomic charges were computed using the OPLS-AA force field.
2.12. Docking simulations
Docking of 2A and 3B into PPARc LBD was performed with the
GOLD software, which uses a genetic algorithm (GA) for determin-
ing the docking modes of ligands and proteins. The coordinates of
the cocrystallized ligand LT175 were chosen as active-site origin.
The active-site radius was set equal to 8 Å. Each GA run used the
default parameters of 100,000 genetic operations on an initial pop-
ulation of 100 members divided into five subpopulations, with
weights for crossover, mutation, and migration being set to 95,
95, and 10, respectively. GOLD allows a user-definable number of
GA runs per ligand, each of which starts from a different orienta-
tion. For these experiments, the number of GA runs was set to
200 without the option of early termination, and scoring of the
docked poses was performed with the original ChemPLP scoring
function followed by rescoring with ChemScore [36–40]. The final
receptor–ligand complex for each ligand was chosen interactively
by selecting the highest scoring pose that was consistent with
experimentally-derived information about the binding mode of
the ligand.
2.13. Statistical analysis of the in vitro assays
All experiments were performed in triplicate with three biolog-
ical replicates. Data from viability, flow cytometry, Western blot-
ting and transient transfection experiments were expressed as
mean ± SD. Data between two groups were assessed using Stu-
dent’s t test. P-values less than 0.05 were considered significant.
Particularly, cell viability of Fig. 2A was analyzed comparing1.2 
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an cladosporol A. (A) Dose-dependent cytotoxicity of cladosporol A and B on HT-29
ed in 96-well plates in order to reach the density of cells/cm2 in standard conditions.
lM) and the growth was evaluated up to 72 h through measurement of absorbance
treated and control cells. Each point was performed in triplicate and the experiment
ssess the effect of cladosporol A and B on exponentially growing HT-29 cells, cells
ed and counted. The data shown here are mean ± SD of 3 experiments performed in
< 0.005 compared with control.
26 D. Zurlo et al. / Biochemical Pharmacology 108 (2016) 22–35time-dependent concentration effects. A one-Way ANOVA test was
performed and referred to time points while Student’s test was
realized between experimental groups in comparison with the cor-
responding control. Asterisks reported in the figure show signifi-
cance degrees, set to P < 0.05.3. Results
3.1. Cladosporol B inhibits the growth of human HT-29 cell line
To investigate whether cladosporol B is endowed with antipro-
liferative activity as cladosporol A, we assessed the growth of colon
carcinoma HT-29 cells treated for different time points (24, 48 and
72 h) with increasing concentrations of the compound. Cladosporol
B greatly reduced cell proliferation with IC50 values of 2.32 lM,
3.16 lM and 2.03 lM for 24, 48 and 72 h long treatments, respec-
tively, as evaluated by the Cell Titer Aqueous One Cell Proliferation
Assay (Fig. 2A). In similar experiments, cladosporol A displayed
IC50 values of 13.85 lM, 12.35 lM and 6.9 lM for 24, 48 and
72 h treatments, respectively [7]. To confirm these results, we trea-
ted HT-29 cells with increasing concentrations of cladosporol B or
A for 8, 24, 48 and 72 h and counted the surviving cells. Their
number diminished in a dose- and time-dependent manner as
compared to untreated cells; the reduction was particularly evi-
dent at the highest concentrations (Fig. 2B); exposure to 10 lM
cladosporol B for 48 h, indeed, inhibited cell proliferation of about
90%, whereas for cladosporol A, at the same dosage and for the
same time, the inhibition was about 50%. These results demon-
strate that cladosporol B inhibits cell proliferation more than
cladosporol A.A B Cladosporol B 
Fig. 3. Cladosporol B induces a G0/G1-phase growth arrest during cell cycle. (A) Cell cy
treated or not with 2.5 and 5 lM cladosporol B, for 4, 8, 12, 24 and 48 h. Data are mean ±
compared with control. (B) Western blotting analysis on total protein extracts produced
(upper panel) and 2.5, 5 and 10 lM cladosporol B (lower panel) for 4, 8, 24 and 48 h. An a
The Western blotting assay reported here is representative of a single exemplificative ex
and cladosporol B-treated HT-29 cells and normalize the results, an anti-b-actin antibo
independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001 compared with control.3.2. Cladosporol B induces a G1-phase growth arrest during cell cycle
To identify the cell cycle changes underlying the observed
growth inhibition, HT-29 cells were cultured in proliferating med-
ium for 24 h, synchronized by serum starvation for 48 h and
exposed to a medium containing 10% FBS and different concentra-
tions of cladosporol B. Exposure to the compound at 2.5 and 5 lM
caused a significant increase in the G0/G1 cell population and a
concomitant decrease in the S- and G2/M phase populations with
respect to untreated cells as assessed by flow cytometry (Fig. 3A).
The percentage of G0/G1 cells, after treatment with 2.5 lM cla-
dosporol B for 4, 8, 12 h, was 80.2%, 76.2% and 65.5%, respectively;
after treatment with 5 lM for the same times, the values were
84.8%, 84.6% and 66.4%; in contrast, the percentage of G0/G1 cell
population in proliferating cells taken as a control showed lower
values as 76.3%, 64.8% and 45.7% after 4, 8 and 12 h, respectively,
suggesting that the treated cells display a delayed entry in the cell
cycle. It is conceivable that the decrease in the G0/G1 population
observed at 24 and 48 h upon treatment was due to cell cycle with-
drawal and enhanced cell death. We already reported that expo-
sure to 20 lM cladosporol A caused a significant increase in the
G0/G1 phase and a parallel decrease in the S and G2/M phase cell
populations [7]. Comparing the results obtained with the two com-
pounds, cladosporol B displays a more powerful activity in arrest-
ing HT-29 cell cycle.
To elucidate the molecular mechanisms underlying the
reported effects, we assessed the expression of p21waf1/cip1, a speci-
fic cell-cycle control protein, by Western blotting assay on extracts
from proliferating HT-29 cells treated for different times with
increasing concentrations of the drug (Fig. 3B). A slight increasecle distribution of HT-29 cells, firstly synchronized by serum deprivation and then
SD of 3 different experiments performed in duplicate. *P < 0.05, **P < 0.01, ***P < 0.005
from proliferating HT-29 cells treated or not with 5, 10 and 20 lM cladosporol A
nti-p21 antibody was used to probe untreated and cladosporol-treated HT-29 cells.
periment. To control the samples loaded derived from untreated and cladosporol A-
dy was used. The bar graphs represent the mean ± SD of p21/b-actin of at least 3
D. Zurlo et al. / Biochemical Pharmacology 108 (2016) 22–35 27in p21waf1/cip1 expression was already detectable with 2.5 lM cla-
dosporol B while it was more robust upon exposure to 5 and
10 lM for 4 and 8 h. The elevation was visible even after 24 and
48 h treatments only with 10 lM cladosporol B. In contrast, the
increase in p21waf1/cip1 expression occurred only upon exposure
to 20 lM cladosporol A for 4, 8, 24 and 48 h and was less pro-
nounced. The p21waf1/cip1 levels started to decline to undetectable
levels at 48 h with both compounds. These results indicate that
cladosporol B induces a more robust cell cycle arrest than cla-
dosporol A likely due to a stronger stimulation of p21waf1/cip1
expression.3.3. Cladosporol B stimulates apoptosis of HT-29 cells
The progressive reduction in surviving HT-29 cells caused by
cladosporol B (2.5 and 5 lM) and cladosporol A (20 lM) (see
Fig. 2B) is accompanied by a time- and dose-dependent appearance
of a sub-G0/G1 peak, a typical feature of the late phase of apoptosis24h
48h
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Fig. 4. Cladosporol B stimulates apoptosis of HT-29 cells. (A) Flow cytometric analysis of
treatment with rosiglitazone (RGZ), cladosporol A and cladosporol B, respectively. HT-29
propidium iodide and analyzed by FACS. *P < 0.05, **P < 0.01, ***P < 0.005 compared with c
for 24 h with the indicated doses of rosiglitazone (RGZ), cladosporol A and cladosporol B, r
apoptotic (lower) cells were evaluated in percentages and reported in the graphic rep
activation performed by Western blotting analysis on total protein extracts produced fro
rosiglitazone (RGZ), cladosporol A and cladosporol B, respectively, is shown. Anti-caspase
part). In the upper part of the figure, normalization of the samples loaded on the gel, p
**P < 0.01, ***P < 0.005 compared with control. (D) DNA fragmentation assay on HT-29 cell
After extraction, DNA was electrophoresed in a 1.0% agarose gel, stained with ethidium br
representative of 3 experiments performed in duplicate and they were normalized by de
control. *P < 0.05 and **P < 0.01.(Fig. 4A). Cladosporol B induced a more remarkable increase in this
subpopulation than cladosporol A and rosiglitazone (RGZ) a well-
known full PPARc agonist used as control. To further verify this,
the cells were stained with Annexin V-FITC and propidium iodide
and analyzed by flow cytometry (Fig. 4B, lower graph): cladosporol
B induced a higher number of Annexin +/propidium + cells, i.e.
apoptotic cells, than the isoform A. In the same analysis, we also
evaluated the amount of necrotic cells following treatment with
different doses of cladosporol B. Their number did not significantly
change ruling out necrosis as an alternative mode of cell death
induced by cladosporol B (Fig. 4B, upper graph). Finally, we ana-
lyzed the levels of caspase-3 precursor, one of the effectors of the
apoptotic process. A significant decrease in the caspase-3 precursor
levels was detected in western blot analysis of HT-29 cells treated
with both drugs for 12, 24 and 48 h (Fig. 4C). Caspase-3 activation
causes maturation of CAD (caspase-activated deoxyribonuclease)
that, in turn, produces DNA fragmentation. Cladosporol B displayed
a higher degradative activity than cladosporol A in accordance with0 
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resentations. *P < 0.05 and **P < 0.01, ***P < 0.005. (C) An analysis of Pro caspase-3
m proliferating HT-29 cells treated or not, for 12, 24 and 48 h, with 5, 10 and 20 lM
3 antibody was used to probe untreated and cladosporol-treated HT-29 cells (lower
erformed by Western blotting using an anti-b-actin antibody, is reported. *P < 0.05,
s treated for the indicated hours with 20 lM cladosporol A and 5 lM cladosporol B.
omide and photographed under U.V. illumination. The data reported in the figure are
nsitometric analysis of the bands and referred to the untreated cell sample used as
28 D. Zurlo et al. / Biochemical Pharmacology 108 (2016) 22–35the results above reported (Fig. 4D). Altogether the results demon-
strate that cladosporol B displays a stronger proapoptotic activity
than cladosporol A.3.4. Cladosporol B displays a different PPARc-mediated transcriptional
activity than cladosporol A
We previously reported that cladosporol A acts as a PPARc
ligand and inhibits CRC cell proliferation through modulation of
expression of several cell cycle gatekeepers, cell cycle arrest at
the G1/S transition and b-catenin/T-cell factor (TCF) pathway inac-
tivation [7,8]. To verify that also cladosporol B acts as a PPARc
ligand and investigate possible differences between the two com-
pounds, we transiently transfected HEK293 cells that stably
express an exogenous PPARc1 with the PPRE-TK-luc-reporter plas-
mid. Luciferase activity was measured in the cell extracts upon
treatment for different times with rosiglitazone, cladosporol A
and B, respectively. Cladosporol A displayed the same potency
and efficacy as rosiglitazone, a well-known synthetic ligand of
PPARc (Fig. 5A). Cladosporol B, instead, showed a lower transacti-
vation activity suggesting that cladosporols bind the PPARc LBDA 
C 
Fig. 5. Cladosporol B displays a different PPARc-mediated transcriptional activity than c
stably expressing PPARc1 with the luciferase reporter gene driven by a minimal promote
for 24 h with rosiglitazone (RGZ), cladosporol A and cladosporol B, respectively. The r
normalization to b-galactosidase activity used as control. Data shown are mean ± SD of
relative potency and efficacy of the three drugs (full and partial agonists) used in the e
concentrations (from 0.025 to 1 lM) of cladosporol A (i), B (ii) and rosiglitazone (RGZ) (
with the luciferase reporter gene driven by a minimal promoter containing three copies o
After 24 h of transfection cells were exposed to rosiglitazone (RGZ), cladosporol A and cl
transfections are reported as luciferase activity fold induction after normalization to b-
experiments performed in duplicate. *P < 0.05 and **P < 0.01.with a different strength, with cladosporol A that may be consid-
ered a full agonist, and cladosporol B a partial agonist.
To prove that cladosporols A and B are bona fide PPARc ligands
and to assess their binding affinity, we employed a surface plas-
mon resonance (SPR)-based approach [41]. The acquired sensor-
grams showed that both compounds interact with the protein
(Fig. 5B). Kinetic and thermodynamic parameters of the interac-
tions were calculated for each molecule fitting the experimental
curves to a classical A + B = AB model. Specifically, a thermody-
namic dissociation constant (KD) of 1.19 lM and a kinetic dissoci-
ation constant (koff) of 1.5  103 s1 were obtained for cladosporol
A, suggesting that this compound forms a quite stable complex
with PPARc LBD. A similar behavior was observed for cladosporol
B, even if the measured KD (59.2 lM) and koff (7.8  102 s1)
revealed a significantly lower affinity for PPARc. These data were
referred to those obtained with RGZ as control (KD 0.320 lM and
koff 2.86  102 s1).
To further demonstrate that cladosporols act through PPARc,
we used GW9662, an irreversible inhibitor of this receptor.
Cotreatment of HEK293 cells with rosiglitazone (RGZ) and
GW9662 caused a lower transactivation than that induced by
rosiglitazone-bound PPARc alone (Fig. 5C). A similar reductionB 
ladosporol A. (A) (Upper panel) Transient transfection assay in human HEK293 cells
r containing three copies of PPRE motif. After transfection, cells were treated or not
esults of the transfections are reported as luciferase activity fold induction after
3 independent experiments performed in duplicate. (Lower panel) In the table the
xperiment shown above are reported. (B) Sensorgrams obtained injecting different
iii) on immobilized PPARc. (C) Transient transfection assay in human HEK293 cells
f a PPRE motif, in the presence of the expression plasmid pCDNA3-FLAG-PPARc1wt.
adosporol B, respectively, in the presence or absence of GW9662. The results of the
galactosidase activity used as control. Data shown are mean ± SD of 3 independent
D. Zurlo et al. / Biochemical Pharmacology 108 (2016) 22–35 29(even if smaller than rosiglitazone) was observed when the cells
were pretreated with GW9662 and than exposed to cladosporol
A and B, suggesting that these latter ligands can bind only an
empty PPARc LBD. Altogether these results demonstrate that cla-
dosporol A and B bind PPARcwith a different affinity, likely involv-
ing different domains of the binding pocket and ensuing activation
of different biological pathways.3.5. Proapoptotic activity of cladosporol B is dependent upon PPARc1
activation
To demonstrate that cladosporol B stimulates apoptosis
through the binding to and activation of PPARc, we cultured a
human CRC derived cell line RKO that displays very low PPARc1
expression and a derived clone overexpressing an exogenous
PPARc1 (Fig. 6A), in the presence of rosiglitazone (RGZ), cla-
dosporol A and cladosporol B, respectively, for 24 h. After treat-
ment, cells were stained with Annexin V-FITC and propidium
iodide and analyzed by flow cytometry (Fig. 6B): cladosporol B
induced a higher number of Annexin +/propidium + cells, i.e. apop-
totic cells, than the isoform A and rosiglitazone in both cellular
types. In addition, in PPARc1 overexpressing-RKO cells, the stron-RKO + PPARγ
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actin antibody. The bar graphs represent the mean ± SD of PPARc/b-actin of at least 3 ind
iodide assay performed on RKO cells and its cellular isotype overexpressing PPARc1
respectively, for 24 h (C) Western blotting analysis of p21 expression on total protein e
respectively, using an anti-p21 antibody. Normalization of the loaded samples was perfor
b-actin of at least 3 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.005 comparedger proapoptotic activity induced by cladosporol B was signifi-
cantly reduced by exposure to GW9662 suggesting a PPARc-
dependence.
To further demonstrate that PPARc is significantly involved in
the cell proliferation arrest affecting p21 expression, we analyzed
total protein extracts from proliferating RKO cells treated for 8 h
with 5 lM cladosporol A and B, in the presence or absence of
GW9662. The results reported in Fig. 6 C demonstrate that a signif-
icant accumulation of p21waf1/cip1 protein was due to PPARc, as it
was greatly reduced upon GW9662 treatment. The results also
indicate that the p21waf1/cip1 increase was partly due to PPARc-
independent mechanisms. We conclude that cladosporol B
induces cell cycle arrest through elevation of p21waf1/cip1
expression and induction of apoptosis through PPARc-dependent
and -independent mechanisms.3.6. Ring opening of epoxy-containing cladosporol A and cladosporol B
by DMSO/H2O
As cladosporols A and B contain a highly polar and tensioned
three-membered epoxide ring, they can undergo ring opening
reactions with a broad range of electrophiles and nucleophiles, asRKO+PPARγ
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30 D. Zurlo et al. / Biochemical Pharmacology 108 (2016) 22–35well as with neutral water via an uncatalyzed mechanism. Since
in vitro experiments were carried out with both cladosporols dis-
solved in DMSO, due to their insolubility in other biocompatible
solvents, we examined the DMSO effect on two compounds to
establish whether their biological activity depends on the epoxide
or diol form.
It is well known that DMSO-based nucleophilic epoxide ring
opening leads to an unstable hydroxyalkoxysulfonium intermedi-
ate [42,43] which in the presence of water is converted into a trans
1,2-diol or a hydroxycarbonyl compound (Fig. 7A).
Therefore, cladosporols A and B were dissolved in D2O/DMSO-
d6 (1:1, v/v) and analyzed for 24 h at 25 C by 1H NMR
spectroscopy. The spectra were recorded every hour and the peak
integrated areas were compared with that obtained with tetram-
ethylsilane (TMS) used as an internal standard. After 2 h, a new
species appeared in the two solutions, which was hypothesized
to be the sulfate ester of cladosporol A (compound 1A in Fig. 7B)
and cladosporol B (compound 1B in Fig. 7B) based on the 1H
NMR spectra (Fig. 8). The integral ratio of cladosporol A:1A was
1:3 after 5 h and 1:9 after 10 h, whereas that of cladosporol B:1B
was 1:2 after 5 h and 2:5 after 10 h. The structural differencesA 
B 
Fig. 7. (A) Scheme of epoxide ring opening by DMSO/H2O and (B) mechanism of formatio
in DMSO/H2O.between the two epoxide-containing compounds may be responsi-
ble for the observed differences in the yield of the sulfonium inter-
mediate. The ring opening rate of the hydroxyepoxide cladosporol
A seems to be faster than that of the ketoepoxide cladosporol
B. Further addition of D2O in the NMR tubes yielded the trans diol
2A and hexahydroxy-dihydro-(1,10-binaphthalen)-4-one (2B)
(Fig. 8).
After 24 h, the NMR mixtures, lyophilized and dissolved in
methanol dry, were analyzed by high resolution electrospray ion-
ization mass (HR-ESI-MS). The mass spectrum of cladosporol A
showed peaks at 453 m/z ([M+Na+H]+, 100%), 371 m/z
([MDMSOH2+H]+, 30%) and 353 m/z ([MDMSO+H]+, 30%) cor-
responding to the hydroxyalkoxysulfonium sodiated ion (1A), pen
tahydroxy-tetrahydro-(1,10-binaphthalene)-4,80-dione (2A in
Fig. 7B), and cladosporol A, respectively. The spectrum of the solu-
tion containing cladosporol B gave a molecular peak at 429m/z ([M
+H]+ 100%) corresponding to the hydroxyalkoxysulfonium ion (1B)
and a peak at 369 m/z ([MDMSO+H]+ 40%) corresponding to
derivative 2B.
Fig. 7B illustrates a possible mechanism of degradation of cla-
dosporols A and B in DMSO/H2O to compounds 2A and 2B. Whenn of the new compounds 2A and 2B from cladosporol A and B, respectively, dissolved
Fig. 8. Epoxide ring opening reaction of cladosporol A and B in D2O/DMSO-d6 (1:1, v/v). 1H NMR spectra of the mixtures of (A) cladosporol A (d) and its
hydroxyalkoxysulfonium intermediate 1A ( ) and of (B) cladosporol B (d) and its hydroxyalkoxysulfonium intermediate 1B ( ).
D. Zurlo et al. / Biochemical Pharmacology 108 (2016) 22–35 31cladosporols A and B are attacked by DMSO in a protic medium, the
epoxide oxygen is protonated and the CAO bond is preferably
cleaved between the nucleophile and the adjacent carbon. Accord-
ing to Parker and Isaacs [44] the 80-C@O group of the a,b-
unsaturated system favors the attack of DMSO on the adjacent
70-C carbon. It is to note that in cladosporol B an intramolecular
H-bond between the 50-C@O and the 40-OH groups decreases the
conjugating effect of the 50-C@O group on the epoxide ring, forcing
the DMSO to attack on the same 70-C carbon, as reported above for
cladosporol A. The formation of hydroxyalkoxysulfonium interme-
diates (1A and 1B) can be rationalized as a ‘‘borderline SN2 mech-
anism” [44,45]. This pathway predicts backside attack of DMSO
with inversion at the 70-C carbon atom, which can provide the most
developing carbonium ion character in the transition state. The
hydrolysis of the hydroxyalkoxysulfonium intermediates occurs
by attack of water exclusively to sulfur, yielding compounds 2A
and 2B, respectively. This is in agreement with the results from
the above described NMR and mass spectral analyses.
3.7. Docking of compounds 2A and 2B into PPARc binding pocket
To clarify the molecular mechanism underlying the full or par-
tial agonism of 2A and 2B, respectively, toward PPARc, we under-
took docking studies into the PPARc LBD. Docking runs were
performed with the GOLD 5.2 program [34], in combination with
the ChemPLP scoring function followed by rescoring with ChemS-
core [46]. Docking experiments were carried out using the X-ray
crystallographic structure of PPARc bound to compound LT175
(PDB code: 3B3K) [35].
Compounds 2A and 2B were able to bind PPARc in a fashion
that is distinct from the binding mode of TZDs, such as RGZ, and
appears to be more similar to that of LT175. Although TZDs bind
in a perpendicular fashion to helix 3 (H3), partially wrapping
around H3, compounds 2A and 2B bind in a north–south orienta-tion, parallel to H3. Fig. 9A shows the positioning of 2A into the
canonical ligand-binding pocket of PPARc. The 3-OH of the cyclo-
hexenone ring can form a trifurcated H-bond with Y473 OH,
Y327 OH, and H449 Ne2 groups; this latter group engages the
ligand 4-OH in a further H-bond. The 5-OH is at H-bonding dis-
tance from the C285 SH group on H3. PPARc full agonists, such
as TZDs, generally engage canonical H-bonds with the three resi-
dues H323, H449, and Y473 on the inner surface of helix 12
(H12). These interactions stabilize H12 and are responsible for
PPARc transactivation [47,48]. The 5-OH-dihydronaphthalenone
moiety of 2A is deeply inserted into a specific pocket of the LBD,
previously named ‘‘diphenyl pocket” [35] thereby forming several
favorable hydrophobic interactions. The bottom of the cavity is
delimited by the loop 11/12 and is contoured sidewise by H3 and
H11. Inside the cavity, the 5-OH-dihydronaphthalenone moiety
interacts with L453 of H11, L465 of loop 11–12, and Q286 of H3.
Specifically, the amino group of Q286 makes an amino-aromatic
van der Waals contact with the benzofused ring of the ligand
[49]. A favorable van der Waals contact is also realized by the
dihydronaphthalenone moiety and the M463 side chain, thus
contributing to stabilize the conformation of the loop 11/12. Fur-
thermore, the benzo-fused ring of the 40,50,60,70-tetrahydroxy-
dihydronaphthalenone forms favorable hydrophobic and p–p
stacking interactions with F363 (H7) and F282 (H3) side chains.
Notice that the F282 side chain, in the LT175 crystal structure, is
shifted from the t to the folded g⁄ conformation owing to the rigid
and straight diphenyl group of the ligand [35]. Superposition of the
2A/PPARc complex on the RGZ/PPARc (PDB code 2PRG) and LT175/
PPARc crystal structures shows that the benzo-fused ring of the 5-
OH-dihydronaphthalenone, together with the distal aromatic ring
of LT175, occupies the same region normally occupied by F282 in
the apo-form of the receptor, thus contributing to stabilize the
region including the loop 11/12 [50] (Fig. 9B). It is well known that
differences in the hydrophobic packing of this loop may contribute
A B 
C D 
Fig. 9. Docking of compounds 2A and 2B into the PPARc binding pocket. (A) Binding mode of compound 2A (green sticks) into the PPARc binding site represented as a
bluemarine ribbon model. (B) Ca superposition of the complexes of PPARc with 2A (green sticks), rosiglitazone (RGZ), (darksalmon sticks, PDB code 2PRG) and LT175
(firebrick sticks, PDB code 3B3K). (C) Binding mode of compound 2B (violet sticks) into the PPARc binding site. (D) Ca superposition of the complexes of PPARcwith 2A (green
sticks) and 2B (violet sticks). Only amino acids located within 4 Å of the bound ligand are displayed (white sticks) and labeled. H12 is shown in orange. The X-loop, a flexible
loop region between H20 and H3, and the b-sheet region of the LBD, are displayed. H-bonds discussed in the text are depicted as dashed black lines. (For interpretation of the
references to color in this figure legend, the reader is referred to the web version of this article.)
32 D. Zurlo et al. / Biochemical Pharmacology 108 (2016) 22–35to diverse H12 dynamics [51]. Thus, the potency of 2A is a direct
consequence of a very effective stabilization of H12, through
hydrophobic and electrostatic interactions, thus facilitating the
recruitment of coactivators.
Surprisingly, docking experiments of compound 2B revealed a
different binding mode to PPARc in comparison to compound 2A.
This compoundoccupies the samebinding location of2A, but adopts
an inverted conformation with the 5-OH-dihydronaphthalenone
moiety in proximity of the triad H323, H449 and Y473, and the
naphthalene-pentaol nucleus placed in the PPARc internal cavity
(Fig. 9C). A Ca superposition of the 2A/PPARc and 2B/PPARc com-
plexes is shown in Fig. 9D. The 5-OH group, which is involved in a
buried intramolecular H-bond with the 4-keto group of the ligand,
maintains a correct position to act as a weak H-bond acceptor from
the H449Ne2H imidazole ring and aweakH-bond donor to the S289
OH group. From the opposite side, the naphthalene-pentaol system
makes a number of H-bonds with residues of H3 and loop 11/12. In
particular, the 80-OHestablishes aH-bondwith thebackboneC@Oof
F282 (H3), the 70-OH donates H-bonds to the amide C@O oxygens of
either Q283 or Q286 of H3, and the 60-OH forms a H-bond with the
main chain NH of S464 (loop 11/12). Moreover, the ligand forms
direct van der Waals contacts with the L453, I456, L465, F282,
F363 and M463 residues lining the cavity. It should be noted that
also in the case of 2B, the naphthalene-pentaol moiety occupiesthe same portion of the cavity as the diphenyl group of LT175,
between H3 and the loop 11/12.
Compound 2Bmakes no direct contacts with residues of H12, a
hallmark of traditional TZDs, but preferentially stabilizes H3
through closer hydrophobic contacts or H-bonds made with resi-
dues S289, F282, Q283 and Q286, thus affecting the recruitment
of coactivators and transactivation. In fact, it is a partial agonist
of PPARc with a weaker transcriptional activity [52–54]. This rela-
tionship is in agreement with our previous findings regarding two
enantiomeric ureidofibrate derivatives complexed with PPARc,
showing partial and full agonism, respectively, toward this nuclear
receptor [52]. Even in that case, while the full agonism of one enan-
tiomer could be related to stronger interactions with H11, H12, and
the loop 11/12, the partial agonism of the other enantiomer could
be ascribed to closer contacts with residues of H3.
3.8. Activity of cladosporols A and B does not require PPARc C285
The C285 residue in the PPARc ligand-binding site is essential
for the activity and covalent binding of some PPARc agonists such
as 15d-PGJ2 [55] or partial agonists such as SR2017 (manuscript in
preparation) but not for RGZ. Because PPARc C285 may be impor-
tant for a noncovalent interaction with both cladosporols (com-
pounds 2A and 2B), as inferred from the docking results, we
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Fig. 10. Cladosporol A and B activities do not require PPARc C285. (A) Transient transfection assays in human HEK293 cells were carried out with the luciferase reporter gene
driven by a minimal promoter containing three copies of a PPRE motif, in the presence of the expression plasmid pCDNA3-FLAG-PPARc1wt or its mutant form (C285A). After
24 h of transfection, cells were exposed for further 48 h to rosiglitazone (RGZ), cladosporol A, cladosporol B and SR2017, respectively. The results of the transfections are
reported as luciferase activity fold induction after normalization to b-galactosidase activity used as control. Data shown are mean ± SD of 3 independent experiments
performed in duplicate. *P < 0.05. (B) Cladosporol A and B treatment of HT-29 cells induces an oxidative stress-response. Lipid peroxidation assay. Exponentially growing HT-
29 cells were treated with 1, 5 and 10 lM of RGZ, cladosporol A and cladosporol B, respectively, for 24 h, lysed and lipid peroxidation was measured by the thiobarbituric acid
colorimetric assay. The results are expressed as micromoles of MDA produced/lg of cell proteins. The data represent results obtained in at least three independent
experiments; the error bars indicate standard deviations.
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tors for the wild type or a mutant form (C285A) of PPARc1 into
HEK293 cells exposed or not to cladosporol A and B. Luciferase
activity from cells transfected with the mutant (C285A) was simi-
lar to that fromwild type PPARc1 upon treatment with cladosporol
B (2B); a slight reduction was observed upon treatment with cla-
dosporol A (2A) (Fig. 10A). This result implies that the PPARc activ-
ity of both cladosporols does not depend on the C285 residue.
3.9. Cladosporol A and B treatment of HT-29 cells induces an oxidative
stress-response
We have previously shown that cladosporol A stimulates an
oxidative stress via different mechanisms and induces an adapta-
tive response through activation of the ERK and JNK pathways
[7]. To prove that the parallel treatment with cladosporol A and
B was able to enhance the redox species, we assessed malondialde-
hyde (MDA) production through a lipid peroxidation assay. Both
cladosporols increased the reactive oxygen species (ROS) with cla-
dosporol B (compound 2B) producing a greater accumulation and
confirming the induction of a more intense redox response than
cladosporol A (compound 2A) (Fig. 10B). These results clearly indi-
cate that both compounds 2A and 2B dissolved in DMSO and water
show a powerful oxidative ability and stimulate a strong apoptotic
response, in agreement with the formation of free radical species
for the co-presence of oxidated and reduced species (see Fig. 7B).
4. Discussion
Nuclear receptors generally interact with small molecules that
stimulate (agonists) or inhibit (antagonists) their biological func-
tion. The ligand-mediated activation of NRs strictly depends on
the three-dimensional changes of the LBD structure dictated by
the positional dynamics of the C-terminal H12 and the overall
AF2 activation domain [56]. Stabilization of H12 and, consequently,
presentation of the interacting surface necessary for the displace-
ment of corepressors and concurrent recruitment of coactivators,
in fact, induce transcriptional activation of target genes. This
scheme applies also to PPARs [50,57]; in this case, ligands can
induce either a full or a partial response, triggering pathwaysinvolved in diverse cellular processes. Structural studies of
ligand-bound PPARs, indeed, are crucial to understand how this
interaction influences the dynamics of the local protein domains
and which biological responses may be affected in terms of effi-
ciency of gene expression activation (genomic response) or ability
of the receptor to interact with different protein partners (non-
genomic response). For these reasons, up to date full or partial ago-
nists and antagonists responsible for the wide spectrum of actions
of PPARs (including the PPARc isoform) have been recognized [57].
The data reported in the present study demonstrate that the
epoxide ring-opened derivatives 2A and 2B, generated by the cor-
responding cladosporols A and B when dissolved in DMSO/water
(Fig. 7B), act as bona fide PPARc ligands as documented by transac-
tivation assays and SPR analysis (Fig. 5). In particular, we provide
evidence that they differentially bind the PPARc LBD eliciting dis-
tinctive, biological responses (Figs. 2–4 and 6). We define here for
the first time the molecular interactions occurring between these
natural ligands and the different functional amino acids lining
the PPARc LBD. Specifically, we found that compound 2A (Fig. 9B)
interacts with PPARc differently from RGZ, but similarly to LT175,
a synthetic partial PPARc ligand [35]. RGZ, in fact, usually binds in
a perpendicular fashion to H3, partially wrapping around the helix;
compound 2A, instead, binds in a north–south orientation, and
runs in parallel with H3. The ligand engages canonical H-bonds
with residues Y473, H449, and H327 on the inner surface of H12,
and stabilizes the region including the loop 11/12, thus contribut-
ing to establish the network of contacts required for ordering the
activation of H12 that allows recruitment of coactivators [51].
Although the binding of 2A to the receptor is different from RGZ,
the resulting biological properties are comparable: in fact, both
molecules exhibit similar sensorgrams at SPR, activate PPARc and
stimulate transcription of a PPRE-driven luciferase reporter gene
at the same extent (Fig. 5A and B). The potency and the efficacy
of compound 2A indeed appear to be a direct consequence of a very
effective stabilization of H12. Furthermore, we have already shown
that cladosporol A, and hence its derivate compound 2A, displays
anticancer activities in various human colon cancer cell lines,
through modulation of several cell cycle gatekeepers gene expres-
sion (p21waf1/cip1, cyclin D1, cyclin E, CDK2, CDK4) [7,8], as reported
in RGZ-treated cells [16,17].
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compound 2B into PPARc (Fig. 9C) revealed a different binding
mode. This compound, in fact, occupies the same location as 2A,
but adopts an inverted conformation with the 5-OH-
dihydronaphthalenone moiety in proximity of the triad Y473,
H449 and H323, and the naphthalene-pentaol nucleus placed in
the PPARc more internal cavity (Fig. 9D). Interestingly, this com-
pound makes no direct contacts with H12 residues, a hallmark of
traditional TZDs, but preferentially stabilizes H3 through closer
hydrophobic contacts or H-bonds made with residues of this helix
(S289, F282, Q283 and Q286), likely affecting coactivator recruit-
ment and transactivation potential [52–54]. Consistently, com-
pound 2B may be considered a PPARc partial agonist and indeed
displays a weaker transactivation profile than 2A (Fig. 5). PPARc
agonists such as 15d-PGJ2 [55] or partial agonists such as SR2017
(manuscript in preparation), but not rosiglitazone, require C285
to covalently bind PPARc, whereas the transactivation activity of
both cladosporols A and B does not depend on this cysteine residue
(Fig. 10A).
One of the key questions about the molecular mechanisms of
PPARc action is how various ligands can affect the recruitment of
different coregulators that, in turn, differentially stimulate tran-
scription of selected groups of genes [20]. Multiple PPARc coactiva-
tors have been identified so far, but it seems unlikely that each
coactivator may regulate a single pathway; more conceivably,
diverse coregulators cooperate to activate gene transcription. The
identification of SPPARMs implies a different affinity for the
ligand-bound receptor to achieve partial or full activation
[20,58]. This differential result could be due to the conformational
changes of the PPARc LBD induced by ligands unveiling a dynamic
response of the receptor. Finally, recent studies have shown that,
upon binding of specific ligands, the interactions between PPARc
and coregulators often depend on their amount present in a given
cell, explaining why a ligand can function as a partial or full agonist
[59–61]. On the basis of these considerations, it is tempting to
speculate that the differential binding of cladosporol A and B (more
specifically, 2A and 2B) to PPARc may influence the choice of
coregulators through conformational changes induced onto the
LBD that may account for the different pathways they regulate.
More experiments using PPARc mutants in transactivation, co-
immunoprecipitation and ChIp assays are required to highlight
these aspects of our research. These in vitro experiments will likely
provide more cues and verify whether the binding of cladosporol B
(compound 2B) to PPARc and the conformational changes of the
LBD induced may affect the WNT/TCF/b-catenin pathway. We have
already demonstrated that a cladosporol A-bound PPARc
physically interacts with b-catenin stimulating its proteasomal
degradation and subsequent inactivation of downstream target
genes. E-cadherin, accordingly, is upregulated reinforcing cell–cell
interactions [8,62].
A ligand-activated PPARc controls both the intrinsic and extrin-
sic arms of the apoptotic pathways [63]. We already demonstrated
the inhibitory effects of cladosporol A on HT-29 cell proliferation,
suggesting the existence of a regulatory circuit that culminates
into cell growth inhibition [7]. We also proposed that ROS genera-
tion was due to the activation of NADPH oxidase, the main enzy-
matic machinery responsible for the production of oxidant
species [7]. A TZD-activated PPARc has been reported to activate
transcription of the proline oxidase/proline dehydrogenase (POX/
PRODH) gene, generating mitochondrial superoxide production
and triggering apoptosis through both the mitochondrial and death
receptor pathways [64]. In addition to being more active than 2A in
arresting HT-29 cell cycle, compound 2B induced also a more
robust apoptosis and a more intense redox response (Fig. 10).
These latter stronger properties of compound 3B (Figs. 2–4) might
be due to its partial agonism and to the differential redox response.We cannot exclude at the moment that cladosporols A and B may
differentially activate POX/PRODH gene transcription, triggering
different levels of apoptosis. Additional experiments will be neces-
sary to detail the changes of the apoptotic pathways induced by
cladosporols.
In summary, we report here for the first time the identification
of a natural compound, cladosporol B, that acts as a PPARc partial
agonist. By different means we show that cladosporol B behaves
differently from its reduced form (cladosporol A) with a lower
transactivation potential but a higher antiproliferative and anti-
apoptotic activity. Epoxide-containing cladosporols A and B are
unstable in DMSO/H2O solution, converting completely to the
ring-opened compounds 2A and 2B. Their structures were con-
firmed via 1H NMR and HR-ESI-MS. The analysis of the structural
features of the binding to the PPARc LBD shows that cladosporol
B interacts differently from full agonists cladosporol A and rosigli-
tazone. This diverse mode of binding may influence the structure
of the LBD and the recruitment of transcription complexes activat-
ing distinct pathways. This study may pave the way to identify and
further characterize novel natural compounds endowed with
stronger biological activities than synthetic and natural available
ligands without the undesired side-effects.Acknowledgements
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